EUCTR2006-000192-14-AT进行中（未招募）不适用
A Clinical Trial Comparing Cangrelor To Clopidogrel In Subjects WhoRequire Percutaneous Coronary Intervention - Champion PCI
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 9,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or non-pregnant female at least 18 years of age
- •2. Diagnostic coronary angiography demonstrating atherosclerosis amenable to
- •treatment by PCI with or without stent implantation. Importantly, the treating physician must have knowledge of the coronary anatomy and
- •suitability for PCI prior to randomization, except for patients diagnosed with STEMI.
- •Importantly, the treating physician must have knowledge of the coronary anatomy and suitability for PCI prior to randomization, except for patients diagnosed with STEMI.
- •Due to the compelling nature of STEMI and the high likelihood of a percutaneous
- •intervention, these subjects may be randomized on diagnosis, preferably in the
- •emergency department, provided there is no impediment to primary PCI.
- •3. Provide written informed consent before initiation of any study-related procedure
- •hemorrhagic stroke, intra-cranial tumor, cerebral arteriovenous malformation, or
- •intracranial aneurysm; recent (<1 month) trauma or major surgery (including
- •CABG surgery); currently receiving warfarin, active bleeding
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1 . Planned staged PCI procedure where the second stage will occur = 30 days after
- •the first intervention
- •2 Admission planned for <12 hrs following PCI
- •3 Known or suspected pregnancy, or lactating females
- •4. Increased bleeding risk: ischemic stroke within the last year or any previous
- •hemorrhagic stroke, tumor, cerebral arteriovenous malformation, or intracranial
- •aneurysm; recent (<1 month) trauma or major surgery (including bypass surgery);
- •currently receiving warfarin, active bleeding
- •5. Impaired hemostasis: known International Normalized Ratio (INR) >1.5; past or
- •present bleeding disorder (including congenital bleeding disorders such as von
- •Willebrand’s disease or hemophilia, acquired bleeding disorders, and unexplained
- •clinically significant bleeding disorders), thrombocytopenia (platelet count
- •<100,000/µL), or history of thrombocytopenia or neutropenia associated with
- •clopidogrel
- •6. Severe hypertension not adequately controlled by antihypertensive therapy at the
- •time of randomization (systolic blood pressure>180 mm Hg or diastolic blood
- •pressure> 110 mm Hg)
- •7. Receipt of fibrinolytic therapy in the 12 hours preceding randomization
- •8. Receipt of a clopidogrel dose exceeding the maintenance dose (ie, >75 mg) at any
- •time in the 5 days preceding randomization (subjects receiving chronic
- •clopidogrel therapy at a dose of 75 mg are eligible)
- •9. Not a candidate for PCI
- •10. Inability to swallow study capsules
- •11. Allergy, hypersensitivity, or contraindication to clopidogrel, cangrelor, mannitol,
- •sorbitol, or microcrystalline cellulose
- •12. Treatment with other investigational agents or devices within the 30 days
- •preceding randomization, planned use of investigational drugs or devices, or
- •previous enrollment in this trial
- •13. Known alcohol or illicit substance abuse
- •14. Inability to give informed consent or high likelihood of being unavailable for
研究者
相似试验
进行中（未招募）
1 期
A Clinical Trial Comparing Cangrelor To Clopidogrel In Subjects WhoRequire Percutaneous Coronary InterventionEnsayo clínico para comparar cangrelor con clopidogrel en sujetos que precisan una intervención coronaria percutánea - Champion PCIEUCTR2006-000192-14-ESThe Medicines Company
进行中（未招募）
不适用
A Clinical Trial Comparing Cangrelor To Clopidogrel In Subjects WhoRequire Percutaneous Coronary Intervention - Champion PCIEUCTR2006-000192-14-DEThe Medicines Company9,000
招募中
3 期
CHAMPION PCIUnstable AnginaMyocardial InfarctionACTRN12606000343505The Medicines Company9,000
进行中（未招募）
不适用
A clinical trial comparing cangrelor to clopidogrel standard of care therapy in subjects who require percutaneous coronary intervention - PhoenixEUCTR2010-021591-28-ITTHE MEDICINES COMPANY10,900
进行中（未招募）
不适用
A clinical trial comparing cangrelor to clopidogrel in subjects who require percutaneous coronary intervention. - NDSubjects with coronary atherosclerosis who require PCI (with or without stent).MedDRA version: 6.1Level: PTClassification code 10011076EUCTR2006-000192-14-ITTHE MEDICINES COMPANY UK9,000